Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma

Julie Delyon; Mariana Varna; Jean-Paul Feugeas; Aurélie Sadoux; Saliha Yahiaoui; Marie-Pierre Podgorniak; Geoffroy Leclert; Sarra Mazouz Dorval; Nicolas Dumaz; Anne Janin; Samia Mourah; Céleste Lebbé

doi:10.18632/oncotarget.10822

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma

Julie Delyon _, Mariana Varna, Jean-Paul Feugeas, Aurélie Sadoux, Saliha Yahiaoui, Marie-Pierre Podgorniak, Geoffroy Leclert, Sarra Mazouz Dorval, Nicolas Dumaz, Anne Janin, Samia Mourah and Céleste Lebbé

PDF | How to cite

Oncotarget. 2016; 7:48850. https://doi.org/10.18632/oncotarget.10822

Metrics: PDF 2515 views | ?

Present: Due to an error during submission of the revised manuscript, Dr. Jean Soulier’s name was omitted from the author list.

Corrected: Correct author list for this article is available below: Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2016; 7(11): 13069-81. DOI: 10.18632/oncotarget.7541

Julie Delyon^1,2,3, Mariana Varna^4,5,6, Jean-Paul Feugeas^3,7, Aurélie Sadoux¹, Saliha Yahiaoui¹, Marie-Pierre Podgorniak⁸, Geo roy Leclert¹, Sarra Mazouz Dorval^3,9, Nicolas Dumaz^1,3, Jean Soulier^10,11, Anne Janin^4,5,12, Samia Mourah^1,3,8,* and Céleste Lebbé^1,2,3,*

¹ INSERM UMR_S976, Paris, F-75010, France
² AP-HP, Hôpital Saint-Louis, Department of Dermatology, Paris, F-75010, France
³ Université Paris-Diderot, Sorbonne Paris Cité, Paris, F-75013, France
⁴ INSERM UMR_S1165, Paris, F-75010, France
⁵ Université Paris-Diderot, Department of Pathology, UMR_S1165, Paris, F-75010, France
⁶ UMR CNRS 8612, Institut Galien-UFR de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, F-92290, France 7 INSERM UMR_1137, Paris, F-75010, France
⁸ AP-HP, Hôpital Saint-Louis, Laboratoire de Pharmacologie Biologique, Paris, F-75010, France
⁹AP-HP, Hôpital Saint-Louis, Department of Plastic, Reconstructive and Esthetic Surgery, Paris, F-75010, France
¹⁰ AP-HP, Hôpital Saint-Louis, Department of Biological Hematology, Paris, F-75010, France
¹¹ Institute of Hematology (IUH), University Paris-Diderot, Paris, F-75010, France
¹² AP-HP, Hôpital Saint-Louis, Department of Pathology, Paris, F-75010, France
^*These authors have contributed equally to this work

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10822

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma